Biodelivery Sciences International (BDSI) 8.59 $BDSI
2014 FDA Drug Approval Calendar
at The Street - Mon May 12, 8:22AM CDT
A list of drugs under FDA review and scheduled FDA advisory panel meetings.
BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of First Quarter 2014 Financials
PR Newswire - Thu May 08, 5:00PM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2014 with the U.S. Securities and Exchange Commission and, in connection therewith, is providing a review of BDSI's recent achievements and an update on business operations and upcoming milestones for 2014.
BioDelivery Sciences to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
PR Newswire - Thu May 08, 6:00AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at the Bank of America Merrill Lynch 2014 Health Care Conference. The presentation is scheduled for Tuesday, May 13, 2014 at 8:40 a.m. Pacific Time (11:40 a.m. Eastern Time) at Encore at Wynn in Las Vegas.
BioDelivery Sciences Announces Randomization of Over 50% of Subjects in its Initial Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy
PR Newswire - Tue May 06, 6:00AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has randomized more than half of the planned number of patients required for its ongoing initial Phase 3 study of Clonidine Topical Gel, BDSI's proposed treatment for painful diabetic neuropathy (PDN).
3 Stocks Under $10 Moving Higher
at The Street - Wed Apr 30, 5:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Global Opium (Opioid) Addiction Therapeutics Pipeline Review 2014
M2 - Mon Apr 28, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bcl2wq/opium_opioid) has announced the addition of the "Global Opium (Opioid) Addiction Therapeutics Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Opium (Opioid) Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opium (Opioid) Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Opium (Opioid) Addiction and enlists all their major and minor projects Companies Involved in Therapeutics Development - BioDelivery Sciences International, Inc. - Nanotherapeutics, Inc. - Acura Pharmaceuticals, Inc. - IntelGenx Corp. - Catalyst Pharmaceutical Partners, Inc. - Camurus AB - Omeros Corporation - D&A Pharma SAS - Reckitt Benckiser Pharmaceutical, Inc. - Relmada Therapeutics, Inc. - Celtic Pharmaceutical Holdings L.P. - Foresee Pharmaceuticals, LLC Drug Profiles - (buprenorphine naloxone) - TA-CD - OMS-403 - buprenorphine hydrochloride - RBP-6300 - OMS-405 - MAL - (buprenorphine hydrochloride naloxone hydrochloride) - CPP-115 - OMS-527 - buprenorphine hydrochloride ER - Ibogaine Analog - Heroin Vaccine - FP-004 - INT-0027 - methadone IR - Synthetic Peptides to Activate DOR and MOR and Inhibit MRP-1 for Oncology and Morphine Addiction - Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction For more information visit http://www.researchandmarkets.com/research/bc...ium_opioid
Global Osteoarthritis Pain Therapeutics Pipeline Review 2014 - Analysis of 32 Companies & 53 Drug Profiles
M2 - Mon Apr 28, 4:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r39xgv/osteoarthritis) has announced the addition of the "Osteoarthritis Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoarthritis Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Osteoarthritis Pain and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Osteoarthritis Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Johnson & Johnson - Allergan, Inc. - Sanofi - Eli Lilly and Company - BioDelivery Sciences International, Inc. - Purdue Pharma L.P. - Teva Pharmaceutical Industries Limited - A. Menarini Industrie Farmaceutiche Riunite Srl - Addex Therapeutics - Nuvo Research Inc. - Elite Pharmaceuticals, Inc. - Pozen, Inc. - Array BioPharma Inc. - Futura Medical plc - Transition Therapeutics Inc. - AcurePharma AB - Palau Pharma, S.A. - Neurotune AG - QRxPharma Limited - Iroko Pharmaceuticals, LLC - Winston Pharmaceuticals, Inc. - Antibe Therapeutics, Inc. - Flexion Therapeutics, Inc. - AllTranz, Inc. - Afferent Pharmaceuticals, Inc. - iCeutica, Inc. - Rottapharm|Madaus - Theralpha SAS - Creabilis SA - AbbVie Inc. - ARTYX Pharmaceuticals, Inc. - Akron Molecules GmbH Drug Profiles - hydrocodone bitartrate ER - duloxetine hydrochloride DR - buprenorphine hydrochloride - meloxicam nanoformulation - zucapsaicin - diclofenac nanoformulation - ART-144 - (oxycodone naltrexone) - ARRY-797 - (morphine oxycodone) CR - AF-219 - onabotulinumtoxinA - SAR-292833 - ABT-652 - fasitibant chloride - FX-005 - LY-2828360 - triamcinolone acetonide SR - naproxen nanoformulation - OLT-1177 - grapiprant - V-116517 - AKR-202 - (lidocaine tetracaine) - dimiracetam - PA-65020 - mavatrep - AKR-203 - ADX-71943 - TASS For more information visit http://www.researchandmarkets.com/research/r3...oarthritis
Global Migraine Therapeutics Pipeline Review 2014 - Analysis of 40 Companies & 59 Drug Profiles
M2 - Mon Apr 28, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rw5qnf/migraine) has announced the addition of the "Migraine - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Migraine - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Migraine and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Allergan, Inc. - Amgen Inc. - Eli Lilly and Company - Questcor Pharmaceuticals, Inc. - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Merck & Co., Inc. - TheraJect, Inc. - Biofrontera AG - Astellas Pharma Inc. - Dr. Reddy's Laboratories Limited - Pfizer Inc. - Impax Laboratories, Inc. - Revance Therapeutics, Inc. - IntelGenx Corp. - NovaDel Pharma, Inc. - Paladin Labs Inc. - Transcept Pharmaceuticals, Inc. - Pozen, Inc. - D-Pharm Ltd. - Ache Laboratorios Farmaceuticos S/A - Alder Biopharmaceuticals Inc. - CoLucid Pharmaceuticals, Inc. - Charleston Laboratories, Inc. - Pantarhei Bioscience BV - Indus Biotech Private Limited - NeurAxon, Inc. - Noxxon Pharma AG - Monosol Rx, LLC For more information visit http://www.researchandmarkets.com/research/rw5qnf/migraine
3 Biotech Stocks With Upcoming Catalysts
George Budwell, The Motley Fool - Motley Fool - Mon Apr 21, 5:30PM CDT
Biotech stocks are a sucker for a good catalyst. And they don't care what the overall market is doing when it arrives. Share prices can move north or south in a hurry, with little concern for larger market trends. So it's no wonder that investors...
Shares of BDSI Up 42.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Apr 10, 4:44PM CDT
SmarTrend identified an Uptrend for BioDelivery Sciences (NASDAQ:BDSI) on December 3rd, 2013 at $5.21. In approximately 4 months, BioDelivery Sciences has returned 42.61% as of today's recent price of $7.43.
BioDelivery Sciences Announces Four BUNAVAIL Abstracts to be Presented at the 2014 American Society of Addiction Medicine Annual Conference
PR Newswire - Mon Apr 07, 8:40AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that data from clinical studies of BUNAVAIL will be presented at the American Society of Addiction Medicine (ASAM) 45th Annual Medical-Scientific Conference, April 10-13, 2014 in Orlando, Florida.
BioDelivery Sciences' Clonidine in Phase III Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 5:25PM CDT
BioDelivery Sciences enrolled the first patient in the phase III RHAPSODY study that will evaluate clonidine topical gel for the treatment of pain associated with diabetic neuropathy.
BioDelivery Sciences Shares Up 59.6% Since SmarTrend's Buy Recommendation (BDSI)
Comtex SmarTrend(R) - Thu Apr 03, 11:01AM CDT
SmarTrend identified an Uptrend for BioDelivery Sciences (NASDAQ:BDSI) on December 3rd, 2013 at $5.21. In approximately 4 months, BioDelivery Sciences has returned 59.58% as of today's recent price of $8.31.
BioDelivery Sciences and Quintiles Sign Deal for Bunavail - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 10:30AM CDT
BioDelivery Sciences signs deal with Quintiles for supporting the anticipated launch of BioDelivery Sciences' Bunavail
BioDelivery Sciences Announces Commercialization Agreement with Quintiles to Support the Launch of BUNAVAIL in the U.S.
PR Newswire - Thu Mar 27, 6:00AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has entered into an agreement with Quintiles to provide a range of services to support the anticipated launch of BUNAVAIL (buprenorphine and naloxone buccal film), BDSI's proposed maintenance treatment for opioid dependence.
Uptrend Call Working As BioDelivery Sciences Stock Rises 72.5% (BDSI)
Comtex SmarTrend(R) - Thu Mar 20, 9:09AM CDT
SmarTrend identified an Uptrend for BioDelivery Sciences (NASDAQ:BDSI) on December 3rd, 2013 at $5.21. In approximately 4 months, BioDelivery Sciences has returned 72.46% as of today's recent price of $8.99.
The Zacks Analyst Blog Highlights:Oracle, Microsoft, IBM, BioDelivery Sciences International and Endo
PR Newswire - Wed Mar 19, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Oracle Corp. (NYSE:ORCL-Free Report), Microsoft (Nasdaq:MSFT-Free Report),IBM (NYSE:IBM-Free Report), BioDelivery Sciences International, Inc. (Nasdaq:BDSI-Free Report) and Endo (Nasdaq:ENDP-Free Report).
Pipeline Update from BioDelivery Sciences - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 18, 4:00PM CDT
BioDelivery Sciences provided updates on two of its lead candidates containing buprenorphine for opioid dependence and pain management, respectively.
BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its 2013 Annual Report
PR Newswire - Fri Mar 14, 5:30AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has filed its Annual Report on Form 10-K for the year ended December 31, 2013 with the U.S. Securities and Exchange Commission and, in connection therewith, is providing a review of BDSI's 2013 financials and achievements as well as an update on business operations and upcoming milestones for 2014.
2014 FDA Drug Approval Calendar
at The Street - Mon May 12, 8:22AM CDT
A list of drugs under FDA review and scheduled FDA advisory panel meetings.
BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of First Quarter 2014 Financials
PR Newswire - Thu May 08, 5:00PM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2014 with the U.S. Securities and Exchange Commission and, in connection therewith, is providing a review of BDSI's recent achievements and an update on business operations and upcoming milestones for 2014.
BioDelivery Sciences to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
PR Newswire - Thu May 08, 6:00AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at the Bank of America Merrill Lynch 2014 Health Care Conference. The presentation is scheduled for Tuesday, May 13, 2014 at 8:40 a.m. Pacific Time (11:40 a.m. Eastern Time) at Encore at Wynn in Las Vegas.
BioDelivery Sciences Announces Randomization of Over 50% of Subjects in its Initial Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy
PR Newswire - Tue May 06, 6:00AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has randomized more than half of the planned number of patients required for its ongoing initial Phase 3 study of Clonidine Topical Gel, BDSI's proposed treatment for painful diabetic neuropathy (PDN).
3 Stocks Under $10 Moving Higher
at The Street - Wed Apr 30, 5:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Global Opium (Opioid) Addiction Therapeutics Pipeline Review 2014
M2 - Mon Apr 28, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bcl2wq/opium_opioid) has announced the addition of the "Global Opium (Opioid) Addiction Therapeutics Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Opium (Opioid) Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opium (Opioid) Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Opium (Opioid) Addiction and enlists all their major and minor projects Companies Involved in Therapeutics Development - BioDelivery Sciences International, Inc. - Nanotherapeutics, Inc. - Acura Pharmaceuticals, Inc. - IntelGenx Corp. - Catalyst Pharmaceutical Partners, Inc. - Camurus AB - Omeros Corporation - D&A Pharma SAS - Reckitt Benckiser Pharmaceutical, Inc. - Relmada Therapeutics, Inc. - Celtic Pharmaceutical Holdings L.P. - Foresee Pharmaceuticals, LLC Drug Profiles - (buprenorphine naloxone) - TA-CD - OMS-403 - buprenorphine hydrochloride - RBP-6300 - OMS-405 - MAL - (buprenorphine hydrochloride naloxone hydrochloride) - CPP-115 - OMS-527 - buprenorphine hydrochloride ER - Ibogaine Analog - Heroin Vaccine - FP-004 - INT-0027 - methadone IR - Synthetic Peptides to Activate DOR and MOR and Inhibit MRP-1 for Oncology and Morphine Addiction - Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction For more information visit http://www.researchandmarkets.com/research/bc...ium_opioid
Global Osteoarthritis Pain Therapeutics Pipeline Review 2014 - Analysis of 32 Companies & 53 Drug Profiles
M2 - Mon Apr 28, 4:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r39xgv/osteoarthritis) has announced the addition of the "Osteoarthritis Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoarthritis Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Osteoarthritis Pain and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Osteoarthritis Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Johnson & Johnson - Allergan, Inc. - Sanofi - Eli Lilly and Company - BioDelivery Sciences International, Inc. - Purdue Pharma L.P. - Teva Pharmaceutical Industries Limited - A. Menarini Industrie Farmaceutiche Riunite Srl - Addex Therapeutics - Nuvo Research Inc. - Elite Pharmaceuticals, Inc. - Pozen, Inc. - Array BioPharma Inc. - Futura Medical plc - Transition Therapeutics Inc. - AcurePharma AB - Palau Pharma, S.A. - Neurotune AG - QRxPharma Limited - Iroko Pharmaceuticals, LLC - Winston Pharmaceuticals, Inc. - Antibe Therapeutics, Inc. - Flexion Therapeutics, Inc. - AllTranz, Inc. - Afferent Pharmaceuticals, Inc. - iCeutica, Inc. - Rottapharm|Madaus - Theralpha SAS - Creabilis SA - AbbVie Inc. - ARTYX Pharmaceuticals, Inc. - Akron Molecules GmbH Drug Profiles - hydrocodone bitartrate ER - duloxetine hydrochloride DR - buprenorphine hydrochloride - meloxicam nanoformulation - zucapsaicin - diclofenac nanoformulation - ART-144 - (oxycodone naltrexone) - ARRY-797 - (morphine oxycodone) CR - AF-219 - onabotulinumtoxinA - SAR-292833 - ABT-652 - fasitibant chloride - FX-005 - LY-2828360 - triamcinolone acetonide SR - naproxen nanoformulation - OLT-1177 - grapiprant - V-116517 - AKR-202 - (lidocaine tetracaine) - dimiracetam - PA-65020 - mavatrep - AKR-203 - ADX-71943 - TASS For more information visit http://www.researchandmarkets.com/research/r3...oarthritis
Global Migraine Therapeutics Pipeline Review 2014 - Analysis of 40 Companies & 59 Drug Profiles
M2 - Mon Apr 28, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rw5qnf/migraine) has announced the addition of the "Migraine - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Migraine - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Migraine and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Allergan, Inc. - Amgen Inc. - Eli Lilly and Company - Questcor Pharmaceuticals, Inc. - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Merck & Co., Inc. - TheraJect, Inc. - Biofrontera AG - Astellas Pharma Inc. - Dr. Reddy's Laboratories Limited - Pfizer Inc. - Impax Laboratories, Inc. - Revance Therapeutics, Inc. - IntelGenx Corp. - NovaDel Pharma, Inc. - Paladin Labs Inc. - Transcept Pharmaceuticals, Inc. - Pozen, Inc. - D-Pharm Ltd. - Ache Laboratorios Farmaceuticos S/A - Alder Biopharmaceuticals Inc. - CoLucid Pharmaceuticals, Inc. - Charleston Laboratories, Inc. - Pantarhei Bioscience BV - Indus Biotech Private Limited - NeurAxon, Inc. - Noxxon Pharma AG - Monosol Rx, LLC For more information visit http://www.researchandmarkets.com/research/rw5qnf/migraine
3 Biotech Stocks With Upcoming Catalysts
George Budwell, The Motley Fool - Motley Fool - Mon Apr 21, 5:30PM CDT
Biotech stocks are a sucker for a good catalyst. And they don't care what the overall market is doing when it arrives. Share prices can move north or south in a hurry, with little concern for larger market trends. So it's no wonder that investors...
Shares of BDSI Up 42.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Apr 10, 4:44PM CDT
SmarTrend identified an Uptrend for BioDelivery Sciences (NASDAQ:BDSI) on December 3rd, 2013 at $5.21. In approximately 4 months, BioDelivery Sciences has returned 42.61% as of today's recent price of $7.43.
BioDelivery Sciences Announces Four BUNAVAIL Abstracts to be Presented at the 2014 American Society of Addiction Medicine Annual Conference
PR Newswire - Mon Apr 07, 8:40AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that data from clinical studies of BUNAVAIL will be presented at the American Society of Addiction Medicine (ASAM) 45th Annual Medical-Scientific Conference, April 10-13, 2014 in Orlando, Florida.
BioDelivery Sciences' Clonidine in Phase III Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 5:25PM CDT
BioDelivery Sciences enrolled the first patient in the phase III RHAPSODY study that will evaluate clonidine topical gel for the treatment of pain associated with diabetic neuropathy.
BioDelivery Sciences Shares Up 59.6% Since SmarTrend's Buy Recommendation (BDSI)
Comtex SmarTrend(R) - Thu Apr 03, 11:01AM CDT
SmarTrend identified an Uptrend for BioDelivery Sciences (NASDAQ:BDSI) on December 3rd, 2013 at $5.21. In approximately 4 months, BioDelivery Sciences has returned 59.58% as of today's recent price of $8.31.
BioDelivery Sciences and Quintiles Sign Deal for Bunavail - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 10:30AM CDT
BioDelivery Sciences signs deal with Quintiles for supporting the anticipated launch of BioDelivery Sciences' Bunavail
BioDelivery Sciences Announces Commercialization Agreement with Quintiles to Support the Launch of BUNAVAIL in the U.S.
PR Newswire - Thu Mar 27, 6:00AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has entered into an agreement with Quintiles to provide a range of services to support the anticipated launch of BUNAVAIL (buprenorphine and naloxone buccal film), BDSI's proposed maintenance treatment for opioid dependence.
Uptrend Call Working As BioDelivery Sciences Stock Rises 72.5% (BDSI)
Comtex SmarTrend(R) - Thu Mar 20, 9:09AM CDT
SmarTrend identified an Uptrend for BioDelivery Sciences (NASDAQ:BDSI) on December 3rd, 2013 at $5.21. In approximately 4 months, BioDelivery Sciences has returned 72.46% as of today's recent price of $8.99.
The Zacks Analyst Blog Highlights:Oracle, Microsoft, IBM, BioDelivery Sciences International and Endo
PR Newswire - Wed Mar 19, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Oracle Corp. (NYSE:ORCL-Free Report), Microsoft (Nasdaq:MSFT-Free Report),IBM (NYSE:IBM-Free Report), BioDelivery Sciences International, Inc. (Nasdaq:BDSI-Free Report) and Endo (Nasdaq:ENDP-Free Report).
Pipeline Update from BioDelivery Sciences - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 18, 4:00PM CDT
BioDelivery Sciences provided updates on two of its lead candidates containing buprenorphine for opioid dependence and pain management, respectively.
BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its 2013 Annual Report
PR Newswire - Fri Mar 14, 5:30AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has filed its Annual Report on Form 10-K for the year ended December 31, 2013 with the U.S. Securities and Exchange Commission and, in connection therewith, is providing a review of BDSI's 2013 financials and achievements as well as an update on business operations and upcoming milestones for 2014.
